Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients

Article Abstract:

Zidovudine and alpha-interferon may prolong life in patients with adult T-cell leukemia/lymphoma (ATL). ATL is caused by the human T-cell lymphotropic virus type I. The disease has four forms: acute, smoldering, chronic and lymphoma. Acute and lymphoma are extremely aggressive forms of the disease that do not respond to chemotherapy and have a poor prognosis. In a study of 10 ATL patients who took zidovudine and alpha-interferon, two patients achieved complete remissions, four achieved partial remissions with a 95% reduction of tumorous cells and two achieved partial remissions with a 50% reduction of tumorous cells.

---

Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa

Article Abstract:

Interferon alfa combined with zidovudine may be effective in treating adult T-cell leukemia-lymphoma. Five patients treated with this combined therapy experienced partial or complete remission. The dose of zidovudine ranged from 500 to 1,000 milligrams (mg) per day; the dose of interferon alpha ranged from 4.5 million to 9 million units per day. Higher doses of both drugs appeared to be more beneficial. This treatment should begin at 1,000 mg/day of zidovudine and 9 million units/day of interferon alfa, and then be adjusted depending on side effects.

Chemotherapy

---

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis

Article Abstract:

A study examines the efficiency and accuracy of high-dose melphalan in comparison with melphaln plus dexamethasone chemotherapy in immunoglobulin-light-chain (AL) amyloidosis is conducted. The high-dose melphalan is found to be a better treatment option than the melphalan plus dexamethasone.

Comparative analysis, Amyloidosis, Dosage and administration, Dexamethasone, Melphalan, Clinical report

Similar abstracts:

• Abstracts: Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine
• Abstracts: Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements
• Abstracts: Screening for chlamydia trachomatis infection in pregnant women in Martinique. Results of a screening program for Chlamydia trachomatis infection in men attending a sexually transmitted diseases clinic
• Abstracts: A controlled trial of zidovudine in primary human immunodeficiency virus infection. Transforming laboratory test results to improve clinical outcome predictions in HIV patients
• Abstracts: The modified biophysical profile: antepartum testing in the 1990s. Cesarean birth: how to reduce the rate

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.